Return to homepagePandemic Pact

Preparation and evaluation of an inactivated COVID-19 vaccine at UVRI and COVAB institutions in Uganda

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-338

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Jennifer Serwanga

  • Research Location

    Uganda

  • Lead Research Institution

    MRC/UVRI and LSHTM Uganda Research Unit

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Representative local and global SARS-CoV-2 virus will be isolated from patients swabs, propagated and cultured on ACE2 Vero cells to produce bulk virus stocks. Virus stocks will be inactivated using b-propiolactone and purified using various steps of chromatography to produce the pure vaccine product. Humanized ACE2 mouse will be immunized, and then challenged with varying doses of the most representative circulating strain of SARS-CoV-2. Immunized mice will be evaluated for safety, protection from disease/death, and for the elicitation of vaccine induced-cellular and humoral immune responses. Safety and vaccine.